Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,675.00
  • Today's Change-5.50 / -0.33%
  • Shares traded291.42k
  • 1 Year change-18.73%
  • Beta0.3450
Data delayed at least 20 minutes, as of Mar 31 2023 17:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hikma Pharmaceuticals PLC is a pharmaceutical company. The Company’s principal activities are the development, manufacturing, marketing and selling of a range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments: Injectables, Generics and Branded. Injectables segment supply hospitals across its markets with generic injectables, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). Generics segment supply oral and other non-injectable generic and specialty branded products in the United States retail market. Branded segment supply branded generics and in-licensed patented products in MENA. It also markets its products in Canada and, which includes approximately 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products.

  • Revenue in GBP (TTM)2.03bn
  • Net income in GBP151.82m
  • Incorporated2005
  • Employees8.84k
  • Location
    Hikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
  • Phone+44 207 399 2760
  • Fax+44 207 399 2761
  • Websitehttps://www.hikma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Genus plc662.40m34.40m1.87bn3.33k54.143.2326.522.820.52420.524210.088.790.6899--5.76199,218.002.793.233.233.80----
Indivior PLC728.42m-42.80m1.87bn928.00--45.56--2.57-0.375-0.3755.040.30180.5011.524.27784,934.40-2.944.76-5.969.1182.3784.35-5.889.421.12-39.100.84450.0013.91-3.79-136.59---32.56--
Worldwide Healthcare Trust PLC-59.72m-84.06m1.93bn0.00--0.8674-----1.28-1.28-0.914935.51-0.0233-------3.287.07-3.577.52--86.92--84.78----0.0010.32-125.52---129.67----3.33
Dechra Pharmaceuticals plc726.80m40.10m2.99bn2.04k73.153.5522.794.110.3590.3596.527.390.49751.676.87356,974.502.743.553.064.0057.1556.745.527.221.4011.540.377996.3512.1413.674.8617.3948.5015.93
Hikma Pharmaceuticals Plc2.03bn151.82m3.68bn8.84k25.042.1311.961.810.66730.66739.037.830.56931.703.36230,065.504.329.135.6812.5450.2650.867.5915.511.146.700.373931.08-1.415.39-55.34--8.301.43
Croda International Plc2.09bn649.30m9.03bn5.83k13.923.7411.674.324.654.6514.9617.300.60512.435.85358,678.1018.9212.8522.0415.0547.1745.6131.2720.161.4323.800.202148.6310.578.76102.4023.14-0.88175.41
Data as of Mar 31 2023. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX

Institutional shareholders

25.89%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 22 Feb 202311.17m5.07%
JPMorgan International Bank Ltd.as of 02 Feb 202310.75m4.88%
BlackRock Advisors (UK) Ltd.as of 22 Feb 20239.14m4.15%
Capital Research & Management Co. (World Investors)as of 02 Feb 20238.37m3.80%
The Vanguard Group, Inc.as of 02 Feb 20234.14m1.88%
Royal London Asset Management Ltd.as of 02 Feb 20233.59m1.63%
FIL Investment Advisors (UK) Ltd.as of 02 Feb 20233.23m1.47%
Capital Research & Management Co. (Global Investors)as of 02 Feb 20232.39m1.08%
Abrdn Alternative Investments Ltd.as of 02 Feb 20232.23m1.01%
Northern Trust Global Investments Ltd. (Securities Lending)as of 02 Feb 20232.02m0.92%
More ▼
Data from 31 Dec 2022 - 02 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.